Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: Retrospective findings from a psychiatric emergency service

American Journal Geriatric Pharmacotherapy

Volumn 3, Issue 4, 2005, Pages 240-245

  Kohen, Izchak ^a,b   Preval, Horacio ^a   Southard, Robert ^a   Francis, Andrew ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

Agitation; Atypical antipsychotic; Haloperidol, geriatric; Ziprasidone

Indexed keywords

HALOPERIDOL; LORAZEPAM; ZIPRASIDONE;

AGED; AGITATION; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; EMERGENCY HEALTH SERVICE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RATING SCALE; RESTLESSNESS; RETROSPECTIVE STUDY; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; UNITED STATES;

EID: 33144466378     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2005.12.006     Document Type: Article

References (29)

1. Alexopoulos G.S. Streim J. Carpenter D. Docherty J.P. Expert Consensus Panel for Using Antipsychotics in Older Patients. Using antipsychotic agents in older patients J Clin Psychiatry 65 Suppl 2 2004 5-104
2. Hamers J.P. Huizing A.R. Why do we use physical restraints in the elderly? Z Gerontol Geriatr 38 2005 19-25
3. Currier G.W. Trenton A. Pharmacological treatment of psychotic agitation CNS Drugs 16 2002 219-228
4. Brook S. Lucey T.V. Gunn K.P. Ziprasidone I.M. Study Group Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis J Clin Psychiatry 61 2000 933-941
5. Weiden P.J. Iqbal N. Mendelowitz A.J. et al. Best clinical practice with ziprasidone: Update after one year of experience J Psychiatr Pract 8 2002 81-97
6. Swift R.H. Harrigan E.P. Cappelleri J.C. et al. Validation of the Behavioural Activity Rating Scale (BARS): A novel measure of activity in agitated patients J Psychiatr Res 36 2002 87-95
7. Kay S.R. Fiszbein A. Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia Schizopbr Bull 13 1987 261-276
8. Daniel D.G. Potkin S.G. Reeves K.R. et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind, randomized trial Psychopharmacology (Berl) 155 2001 128-134
9. Wright P. Meehan K. Birkett M. et al. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy Clin Ther 25 2003 1420-1428
10. May Oren D. Carson W. Stock E. et al. Intramuscular aripiprazole in acutely agitated psychotic patients Atlanta, Ga. 57th Annual Meeting of the American Psychiatric Association 2005
11. Battaglia J. Moss S. Rush J. et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study Am J Emerg Med 15 1997 335-340
12. Schneider L.S. Pollock V.E. Lyness S.A. A meta-analysis of controlled trials of neuroleptic treatment in dementia J Am Geriatr Soc 38 1990 553-563
13. Casey D.E. Motor and mental aspects of acute extrapyramidal syndromes Acta Psychiatr Scand Suppl 380 1994 14-20
14. [published correction appears in J Clin Psychiatry. 2001;62:209] Lasem M.D. Zajecka J.M. Swift R.H. et al. Intramuscular ziprasidone, 20 mg versus 10 mg, in the short-term management of agitated psychotic patients J Clin Psychiatry 62 2001 12-18
15. [published correction appears in CNS Drugs. 2003;17:202] Tarsy D. Baldessarini R.J. Tarazi F.I. Effects of newer antipsychotics on extrapyramidal function CNS Drugs 16 2002 23-45
16. Breier A. Methan K. Birkett M. et al. A double-blind, placebo-controlled dose-response comparison of intra muscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia Arch Gen Psychiatry 59 2002 441-448
17. Moran M. Zyprexa IM caution issued in some countries but not U.S. Psychiatric News 40 2005 1, 66
18. Rosack J. FDA orders new warning on atypical antipsychotics Psychiatric News 40 2005 1
19. Preval H. Klotz S.G. Southard R. Francis A. Rapid-acting IM ziprasidone in a psychiatric emergency service: A naturalistic study Gen Hosp Psychiatry 27 2005 140-144
20. Guy W. Clinical Global Impressions (CGI) American Psychiatric Association, Task Force for the Handbook of Psychiatric Measures Handbook of Psychiatric Measures 2000 American Psychiatric Association Washington, DC 100-102
21. Banazak D.A. Difficult dementia: Six steps to control problem behaviors Geriatrics 51 1996 36-42
22. Fernandez H.H. Trieschmann M.E. Burke M.A. Friedman J.H. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies J Clin Psychiatry 63 2002 513-515
23. Schneider L.S. Tariot P.N. Lyketsos C.G. et al. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology Am J Geriatr Psychiatry 9 2001 346-360
24. Greco K.E. Tune L.E. Brown F.W. Van Horn W.A. A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients J Clin Psychiatry 66 2005 928-929
25. Oechsner M. Korchounov A. Parenteral ziprasidone: A new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease? Hum Psychopharmacol 20 2005 203-205
26. Battaglia J. Pharmacological management of acute agitation Drugs 65 2005 1207-1222
27. Glassman A.H. Bigger J.T. Jr Antipsychotic drugs: Prolonged QTc interval, torsades de pointes, and sudden death Am J Psychiatry 158 2001 1774-1782
28. Brook S. A pilot study of intramuscular ziprasidone in the short-term treatment of patients with acute exacerbation of schizophrenia Hum Psychopharmacol 15 2000 521-524
29. Roe C.M. Odell K.W. Henderson R.R. Concomitant use of antipsychotics and drugs that may prolong the QT interval J Clin Psychopharmacol 23 2003 197-200